Targeting BCMA in multiple myeloma Review
| Authors: | Tan, C. R.; Shah, U. A. |
| Review Title: | Targeting BCMA in multiple myeloma |
| Abstract: | Purpose of Review: Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a significant number of patients still progress on current available therapies. Here, we review treatment modalities used to target BCMA in the treatment of MM, specifically antibody-drug conjugates (ADC), bispecific antibody constructs, and chimeric antibody receptor (CAR) modified T-cell therapies. We will provide an overview of therapies from these classes that have presented or published clinical data, as well as data on mechanisms of resistance to these novel agents. Recent Findings: Clinical trials exploring different BCMA-targeting modalities to treat multiple myeloma are underway and demonstrate promising results. In relapsed/refractory multiple myeloma, anti-BCMA ADCs and bispecific antibody constructs are showing impressive efficacy with manageable side effect profiles. In parallel, adoptive cellular therapy has induced dramatic durable responses in multiply relapsed and refractory myeloma patients. Summary: Therapeutic approaches targeting BCMA hold significant potential in the management of multiple myeloma and will soon be incorporated in combination with current standard therapies to improve outcomes for patients with multiple myeloma. In addition, novel approaches are being evaluated to overcome resistance mechanisms to anti-BCMA therapies. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. |
| Keywords: | overall survival; lenalidomide; thalidomide; neutropenia; review; cytotoxic agent; drug efficacy; drug safety; drug approval; flow cytometry; outcome assessment; cd3 antigen; antigen expression; cell proliferation; t lymphocyte; cell death; dna damage; progression free survival; bortezomib; multiple myeloma; anemia; cell maturation; thrombocytopenia; cyclophosphamide; melphalan; immunoglobulin enhancer binding protein; tumor antigen; pneumonia; clinical study; chimeric antigen receptor; microtubule assembly; bone marrow cell; point mutation; antigen presenting cell; t lymphocyte activation; alemtuzumab; gamma secretase inhibitor; antibody dependent cellular cytotoxicity; carfilzomib; gamma secretase; major histocompatibility antigen class 1; inotuzumab ozogamicin; chimeric antibody; overall response rate; cell disruption; april protein; bispecific antibody; brentuximab vedotin; antibody-drug conjugates; human; vedotin; b cell activating factor; obinutuzumab; b cell maturation antigen; atezolizumab; daratumumab; bcma; keratopathy; antibody drug conjugate; car t cell therapy; belantamab mafodotin; bispecific antibody constructs; pacanalotamab; pavurutamab; teclistamab |
| Journal Title: | Current Hematologic Malignancy Reports |
| Volume: | 16 |
| Issue: | 5 |
| ISSN: | 1558-8211 |
| Publisher: | Springer |
| Date Published: | 2021-10-01 |
| Start Page: | 367 |
| End Page: | 383 |
| Language: | English |
| DOI: | 10.1007/s11899-021-00639-z |
| PUBMED: | 34432234 |
| PROVIDER: | scopus |
| DOI/URL: | |
| Notes: | Review -- Export Date: 1 December 2021 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work